About Enterome
Enterome is a company based in Paris (France) founded in 2008.. Enterome has raised $129.73 million across 7 funding rounds from investors including Takeda Pharmaceuticals, European Investment Bank and Nestlé Health Science. Enterome offers products and services including OncoMimics™ Platform, EO2463, EO4010, and EO2401. Enterome operates in a competitive market with competitors including Moderna, BeiGene, Aclaris Therapeutics, Incyte and Horizon Therapeutics, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$129.73 M (USD)
in 7 rounds
-
Latest Funding Round
$52.25 M (USD), Series E
Jun 25, 2020
-
Investors
Takeda Pharmaceuticals
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enterome
Enterome offers a comprehensive portfolio of products and services, including OncoMimics™ Platform, EO2463, EO4010, and EO2401. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform that generates immune responses for cancer treatments.
Drug for treating B cell malignancies and other tumors.
Therapy targeting colorectal cancer in clinical trials.
Treatment for adrenal tumors and related cancers.
Unlock access to complete
Unlock access to complete
Funding Insights of Enterome
Enterome has successfully raised a total of $129.73M across 7 strategic funding rounds. The most recent funding activity was a Series E round of $52.25 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series E — $52.3M
-
First Round
First Round
(01 Jun 2008)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2020 | Amount | Series E - Enterome | Valuation | Symbiosis , Takeda | |
| Jan, 2018 | Amount | Debt – Conventional - Enterome | Valuation |
investors |
|
| Jan, 2018 | Amount | Series D - Enterome | Valuation | Principia SGR , Bristol-Myers Squibb |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Enterome
Enterome has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Takeda Pharmaceuticals, European Investment Bank and Nestlé Health Science. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Founded Year | Domain | Location | |
|
Private equity firm focused on energy transition and sustainable investments across Europe.
|
Founded Year | Domain | Location | |
|
Early-stage investments in Italian tech and life sciences are targeted.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Enterome
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Enterome
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Enterome Comparisons
Competitors of Enterome
Enterome operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Aclaris Therapeutics, Incyte and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Enterome
Frequently Asked Questions about Enterome
When was Enterome founded?
Enterome was founded in 2008.
Where is Enterome located?
Enterome is headquartered in Paris, France.
Is Enterome a funded company?
Enterome is a funded company, having raised a total of $129.73M across 7 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $48.12M, raised on Jun 01, 2008.
What does Enterome do?
Founded in 2008 and based in Paris, France, Enterome operates in the biotechnology sector. Drugs are developed by decoding interactions between the gut microbiome and the immune system. Two platforms have been established: OncoMimics for therapeutic cancer vaccines and EndoMimics for oral bioactives targeting inflammatory and autoimmune diseases. Focus is placed on immunomodulation for therapeutic applications.
Who are the top competitors of Enterome?
What products or services does Enterome offer?
Enterome offers OncoMimics™ Platform, EO2463, EO4010, and EO2401.
Who are Enterome's investors?
Enterome has 10 investors. Key investors include Takeda Pharmaceuticals, European Investment Bank, Nestlé Health Science, Bristol-Myers Squibb, and Symbiosis.